Welcome to our dedicated page for Oncolytics Biotech Common Shares news (Ticker: ONCY), a resource for investors and traders seeking the latest updates and insights on Oncolytics Biotech Common Shares stock.
Oncolytics Biotech Inc. (symbol: ONCY) is a pioneering biotechnology company dedicated to the development of oncolytic viruses as innovative cancer therapeutics. Their flagship product, pelareorep, is a unique immunotherapeutic agent designed to harness the power of the human reovirus to enhance the body's immune response against cancer. Pelareorep has shown promising potential in making tumors more responsive to a variety of oncology treatments by promoting an inflamed tumor phenotype.
The company's robust clinical development pipeline includes multiple human trials targeting some of the most prevalent cancers, such as breast, gastrointestinal, and pancreatic cancers. Notably, Oncolytics is conducting a Phase III trial for head and neck cancers and has several ongoing trials in advanced stages, including the GOBLET study, which explores the efficacy of pelareorep in combination with different chemotherapy regimens.
In breast cancer, Oncolytics is advancing towards registration-enabling studies for HR+/HER2- metastatic breast cancer, supported by compelling data from the BRACELET-1 and IND-213 randomized studies. The company is also making significant strides in pancreatic cancer research, recently receiving a US$5 million grant from the Pancreatic Cancer Action Network (PanCAN) for a new Phase 1/2 cohort in the GOBLET study, assessing pelareorep in combination with modified FOLFIRINOX and atezolizumab (Tecentriq®).
Financially, Oncolytics is well-positioned with a strong balance sheet and ongoing support from strategic partnerships and grants. The company’s collaborations with leading research institutions and oncology networks enhance its clinical programs and accelerate the development of pelareorep as a versatile cancer therapy. Oncolytics continues to innovate and push the boundaries of cancer treatment, aiming to bring new hope to patients worldwide.
Oncolytics Biotech Inc. (NASDAQ: ONCY) has announced the acceptance of an abstract for an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for June 2-6, 2023 in Chicago, Illinois. The presentation will focus on the BRACELET-1 trial, which evaluates the use of pelareorep in combination with paclitaxel and avelumab for treating metastatic HR+/HER2- breast cancer. Dr. Matt Coffey, CEO, emphasized the significance of this recognition, stating it highlights the trial's importance to oncology stakeholders. The abstract, numbered 1012, will be published on the ASCO website on May 25, 2023. Oncolytics is advancing pelareorep through several clinical trials aimed at enhancing treatment outcomes for various cancers.
Oncolytics Biotech announced that Chief Medical Officer Thomas Heineman will participate in the Viral Immunotherapy – Moving Forward panel at Canaccord Genuity's Horizons in Oncology Virtual Conference on April 20, 2023. The event starts at 9:00 a.m. ET, and a live webcast will be accessible to registered attendees. Company management will also engage in virtual one-on-one investor meetings throughout the conference. Oncolytics is focused on developing pelareorep, an immunotherapeutic agent designed to enhance anti-cancer immune responses for various cancers. The company is advancing clinical trials to evaluate pelareorep in combination with other treatments for conditions like metastatic breast and pancreatic cancer.
Oncolytics Biotech Inc. (NASDAQ: ONCY) will host a conference call and webcast on May 5, 2023, at 8:30 a.m. ET to discuss the first quarter financial results and provide a corporate update. The call can be accessed via toll-free numbers for North America and international callers, and a replay will be available for one week post-event. Oncolytics is developing pelareorep, an immunotherapeutic agent aimed at treating various cancers by inducing anti-cancer immune responses. The company is exploring combinations of pelareorep with checkpoint inhibitors and other oncology treatments, particularly targeting metastatic breast cancer and pancreatic cancer. For further details, visit Oncolytics Biotech's website.
Oncolytics Biotech Inc. (NASDAQ: ONCY) has released its annual general meeting notice, which will take place virtually on May 9, 2023, at 4:00 p.m. Toronto time. Shareholders can view the management information circular on the company's website. Proxy solicitation is being handled by Laurel Hill Advisory Group, with a fee of $35,000 plus expenses. Shareholders are urged to vote before the 4:00 p.m. deadline on May 5, 2023. The board of directors recommends voting for all nominees and resolutions. Oncolytics is focused on developing pelareorep, an immunotherapeutic agent aimed at enhancing anti-cancer immune responses, with ongoing clinical trials.
On March 28, 2023, Oncolytics Biotech Inc. (NASDAQ: ONCY) announced that Dr. Matt Coffey, President and CEO, will participate in the 'Novel Mechanisms with Important Readouts' panel at Cantor Fitzgerald's The Future of Oncology Virtual Symposium from April 3-5, 2023. The panel is scheduled for April 3 at 11:00 a.m. ET. A live webcast and archived replay will be accessible to registered attendees. Oncolytics is advancing clinical trials for its immunotherapeutic agent, pelareorep, which enhances anti-cancer immune responses and targets various cancers, including metastatic breast and pancreatic cancer.
Oncolytics Biotech announced operational highlights and financial results for Q4 and full year 2022, emphasizing progress in its pancreatic and breast cancer programs. Notably, the phase 1/2 GOBLET trial showed a 69% objective response rate in advanced pancreatic cancer, leading to FDA Fast Track designation. The BRACELET-1 trial in metastatic breast cancer is on track for data readout in Q2 2023. As of December 31, 2022, the company reported $32.1 million in cash, providing a runway through anticipated milestones. The net loss for Q4 2022 was $8.6 million, and for the full year, it was $24.8 million, reflecting a decrease in losses compared to 2021.
Oncolytics Biotech (NASDAQ: ONCY) announced a conference call and webcast to discuss its fourth quarter and full year 2022 financial results, scheduled for March 3, 2023, at 8:30 a.m. ET. The call will cover corporate updates and financial insights regarding the company’s lead immunotherapeutic agent, pelareorep, which is in trials for treating various cancers. The company is advancing towards registration studies in metastatic breast cancer and pancreatic cancer while evaluating pelareorep in combination with immune checkpoint inhibitors.
Oncolytics Biotech's partner Adlai Nortye presented interim results from a bridging clinical trial evaluating pelareorep-paclitaxel therapy for advanced HR+/HER2- breast cancer in Chinese patients. Out of 14 evaluable patients, 93% achieved disease control, with 86% showing tumor shrinkage. The median progression-free survival (PFS) was reported at 9.1 months. The combination therapy was well tolerated with no serious adverse events. Upcoming data from the ongoing BRACELET-1 trial are anticipated to further support pelareorep's development towards regulatory approval.
Oncolytics Biotech (NASDAQ: ONCY) announced FDA Fast Track designation for pelareorep combined with atezolizumab, gemcitabine, and nab-paclitaxel to treat advanced pancreatic ductal adenocarcinoma (PDAC). This designation follows a reported 69% objective response rate from their phase 1/2 GOBLET study, significantly higher than the historical average of ~25%. Fast Track status enables more frequent communication with the FDA, potentially leading to Accelerated Approval and Priority Review. Oncolytics is focused on pivotal trials for its core programs in breast and pancreatic cancer.
FAQ
What is the current stock price of Oncolytics Biotech Common Shares (ONCY)?
What is the market cap of Oncolytics Biotech Common Shares (ONCY)?
What is Oncolytics Biotech Inc. known for?
What cancers is Oncolytics currently targeting?
What is pelareorep?
What are the recent achievements of Oncolytics Biotech?
How is Oncolytics Biotech funded?
What is the GOBLET study?
What are the potential benefits of pelareorep?
What is the focus of Oncolytics' current clinical trials?
What partnerships does Oncolytics Biotech have?
Where can I find more information about Oncolytics Biotech?
